CRENESSITY (Crinecerfont) Patent Expiration, LOE Window & CMS Spending

CRENESSITY (Crinecerfont) by Neurocrine Biosciences: FDA Orange Book core substance LOE 2043-01-12, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $38,333 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNeurocrine Biosciences
FDA Application & PathwayN218808 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-01-12
Last Listed Patent or Exclusivity Date2043-01-12
Orange Book Patents (*PED Extensions)15 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($38,333 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.